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Cellular immune responses play a crucial role in the control of viral replication in HIV-infected individuals. However,
the virus succeeds in exploiting the immune system to its advantage and therefore, the host ultimately fails to
control the virus leading to development of terminal AIDS. The virus adopts numerous evasion mechanisms to
hijack the host immune system. We and others recently described the expression of inhibitory molecules on T cells
as a contributing factor for suboptimal T-cell responses in HIV infection both in vitro and in vivo. The expression of
these molecules that negatively impacts the normal functions of the host immune armory and the underlying
signaling pathways associated with their enhanced expression need to be discussed. Targets to restrain the
expression of these molecular markers of immune inhibition is likely to contribute to development of therapeutic
interventions that augment the functionality of host immune cells leading to improved immune control of HIV
infection. In this review, we focus on the functions of inhibitory molecules that are expressed or secreted following
HIV infection such as BTLA, CTLA-4, CD160, IDO, KLRG1, LAG-3, LILRB1, PD-1, TRAIL, TIM-3, and regulatory cytokines,
and highlight their significance in immune inhibition. We also highlight the ensemble of transcriptional factors such
as BATF, BLIMP-1/PRDM1, FoxP3, DTX1 and molecular pathways that facilitate the recruitment and differentiation of
suppressor T cells in response to HIV infection.
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Introduction
Functional senescence of virus-specific T cells and pro-
gressive loss of naïve CD4+ and CD8+ T cells are features
of HIV infection [1]. One effect HIV infection has, is to
facilitate the expansion of suppressor T cells, which com-
promises HIV-specific CD4+ and CD8+ T cell responses
by acting in a contact-dependent manner [2-5]. HIV infec-
tion can alter the survival rates and regenerative capacity
of T cells [6]. A recent study also showed that HIV-infected
T cells serve as migratory vehicles for viral dissemination
[7] and therefore once infected may not contribute to viral
clearance. Importantly, the impairment of effector T-cell
immune functions in HIV infected individuals is reportedly* Correspondence: marie.larsson@liu.se; shivamsarvam@gmail.com
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reproduction in any medium, provided the ormultifactorial [8], and upregulation of negative costimu-
latory and secretory factors and impaired cytokine produc-
tion in HIV-specific T cells and other immune cells is
believed to facilitate rapid disease progression and eventual
systemic immune dysfunction [9,10]. Hence, the expression
of inhibitory molecules on T cells has been proposed as a
contributing factor for the suboptimal T-cell responses seen
in HIV infection [2-6].Unraveling the complexity of T-cell costimulation
The first step of HIV-1 transmission is mucosal exposure
and Langerhans cells lining the genital mucosa, constitute
a front-line defense against invading virus [11,12]. These
dendritic cells (DCs) pick up HIV-1 from mucosal sites,
and migrate to peripheral lymph nodes to activate HIV-
specific naïve T cells. During migration the DC changes its
phenotype and increases the expression of maturation
markers, e.g. CD83, MHC class I and II, costimulatory
molecules, and lymph node homing molecules, e.g. CCR7
(CD197). These events are critical for efficient antigenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[12]. The T cells play a key role in cell-mediated immune
responses, and their activation is multifaceted and requires
distinct signals. The first signal occurs when the TCR rec-
ognizes the antigenic peptide bound to MHC molecules
on APCs. The second signal, the costimulatory signal, can
either be positive or negative, the former necessary for
achieving full T cell activation and initiation of effective
immunity and the latter for the establishment and
maintenance of peripheral tolerance, and abortive T-cell
responses [13]. A balance between positive and negative
costimulatory pathways is required to sustain a normal
protective response and these pathways are therefore at-
tractive therapeutic targets for chronic diseases associated
with immune suppression. The surface receptor CD28 is
the primary costimulatory receptor for initial T-cell expan-
sion and survival and the positive costimulatory signals
provided by CD28 lead to dramatic increase in IL-2 secre-
tion and promote clustering of TCRs, which potentiate
TCR signaling [14]. CD28 binds to B7-1 (CD80) and B7-2
(CD86), expressed exclusively on professional APCs, and
this enhances T-cell proliferation by increasing the
transcription of IL-2 and Bcl-xL [14]. Several other posi-
tive costimulatory molecules besides B7-1 and B7-2 exist
that contribute to promote T cell functions and include
inducible T-cell costimulator (ICOS: CD278), OX40
(CD134), 4-1BB (CD137), and CD40. In addition to the
costimulatory molecules that promote T-cell activationFigure 1 Infection with HIV facilitates the upregulation of inhibitory m
of numerous inhibitory molecules on expanded T cells. The expanded T ce
near vicinity in a contact-dependent manner [4], transforming them into suother molecules exist that instead, regulate and inhibit T-
cell activation. Herein, we review the role of inhibitory
molecules that are expressed on cells or secreted following
HIV-1 infection, and focus on their significance in HIV-
associated immune inhibition. Our recent findings showed
that HIV-1 exposed DCs gave rise to increased expression
of inhibitory molecules on expanded T cells (Figure 1) and
that these T cells had the ability to act in a contact-
dependent manner on T cells present in their vicinity and
suppressed their immune activation [2-4] (Figure 1). We
also highlight the ensemble of repression factors and
molecular pathways that facilitate the recruitment and
differentiation of exhausted T cells in response to HIV-1
infection. The nature of the ensuing immune response
depends on the initial stimuli and the binding amplitude
of TCR-MHC-peptide complex formed during a given
event of antigen presentation and subsequent engagement
of positive or negative costimulatory molecules to their
cognate receptors/ligands [15]. Chronic HIV infection
reportedly induces expression of suppressor/inhibitory mol-
ecules that generate key negative signals that downregulate
the ensuing T-cell responses.
Negative costimulatory molecules
a) PD-1
PD-1 (CD279) is a 50–55 kD glycoprotein that belongs to
the CD28/B7 Ig superfamily. PD-1 expression can be
induced on CD4+ and CD8+ T cells, natural killer cellsolecules in T cells. HIV-1 modulates host DCs to increase expression
lls are suppressor T cells [4] that act on other T cells present in the
ppressor cells and so contributing to eventual T-cell inhibition [3-5].
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are activated [16,17]. The PD-1/PD-L pathway leads to the
transduction of a negative immunoregulatory signal
that antagonizes the TCR-CD28-mediated activation of
phosphatidylinositol 3-kinase (PI3K), which reduce
Akt phosphorylation and glucose metabolism resulting
in inhibition of T-cell activation [18,19] (Figure 2). PD-L2
(B7-DC;CD273) and PD-L1 (B7-H1;CD274) are PD-1
ligands. PD-L2 expression is inducible on DCs and macro-
phages, whereas PD-L1 expression is constitutive on both
professional and non-professional APCs [16,17,20,21]. Sig-
naling via PD-1 occurs only when this receptor is engaged
at the same time as TCR, which is in accordance with
other CD28 family members. The cytoplasmic domain of
PD-1 contains two tyrosine signaling motifs and both are
phosphorylated following receptor engagement [18]. Phos-
phorylation of the second tyrosine, an immunoreceptor
tyrosine-based inhibitory motif (ITSM), recruits SHP-2
and SHP-1 to the PD-1 cytoplasmic domain [18]. This
initiates dephosphorylation of TCR proximal signaling
molecules (e.g. ZAP70, PKCθ, and CD3ζ), leading to
attenuation of the TCR/CD28 signaling cascade [18].
Accumulating lines of evidence suggest that the PD-
1–PD-L1 pathway protects the vascular system from
severe CD8+ T cell–mediated pathology during early
systemic murine lymphocytic choriomeningitis virus
(LCMV) infection. However, the association of PD-1
pathway with cytotoxic T lymphocyte (CTL) inhibition
has opened up investigations on its potential negativeFigure 2 Inhibitory signaling events at the DC-T cell interjunction lea
expressed on APCs and T cells regulate the TCR-mediated signals. CTLA-4 a
leading to decreased IL-2 production and T-cell inhibition. CTLA-4 and PD-
with Akt phosphorylation. PD-1 blocks the activation of phosphatidylinosito
level of T-cell inhibition independent of other inhibitory molecules. LAG-3
TCR signaling and TCR-induced Ca2+-fluxes. 2B4-mediated CD8+ T-cell inhib
adaptor molecule. TRAIL can interact with DR receptors to induce T-cell su
with HVEM inhibits TCR-mediated signaling via ITIM motifs and recruitmen
cell cycle functions of T-cell proliferation. Similarly, TIM-3-galectin9/phospha
to T-cell inhibition.role in HIV infection [4]. It has been shown that PD-1
expression is elevated on SIV-specific CD8+ T cells and
in vivo blockade of the PD-1–PD-L pathway in vivo
leads to increased T-cell proliferation, effector cytokine
production, SIV-specific B-cell responses, and pro-
longed survival [19-22]. CD8+ T cells in HIV-infected
individuals are reportedly dysfunctional with reduced
proliferative capacity and effector functions [23]. In
agreement with this notion, others showed that HIV
disease severity i.e. viral load and declining CD4+ T-cell
counts, correlated with level of both PD-1 expression
on HIV-specific CD8+ T cells and percentage of cells ex-
pressing PD-1, providing a marker on CD8+ T cells that
correlates with disease severity [23]. In addition, PD-1
expression on HIV-specific CD8+ T cells was markedly
reduced in patients on ART, consistent with the notion
that high antigen load drives PD-1 expression and func-
tional exhaustion [23,24]. Importantly, HIV-exposed
DCs induce T-cell inhibition via PD-1/cytotoxic T-
lymphocyte antigen-4 (CTLA-4) signaling [6]. HIV ex-
posure also leads to PD-L1 upregulation and B7-1/B7-2,
and CD40 downregulation on myeloid DCs and this
impairs DC functions, which correlates with disease
progression in chronic HIV infection [25].
We and others have recently proposed that the PD-1
pathway could be manipulated for use in the treatment of
persistent viral infections (PVIs), especially HIV-1 infec-
tion [5,21]. However, there is evidence suggesting that this
pathway protects the vascular system from severe CD8+ Tding to T-cell inhibition in HIV infection. The inhibitory molecules
nd PD-1 recruit the key protein tyrosine kinases SHP-1 and SHP-2
1 block CD28-mediated increase of glucose metabolism by interfering
l-3-kinase and CTLA-4 acting further downstream. LAG-3 induces high
functions by binding to the CD3/TCR complex where it inhibits CD3/
ition occurs via 2B4 binding to CD48 leading to recruitment of EAT2
ppression without initiating apoptosis. Engagement of BTLA on T cells
t of SHP. Likewise CD160 also engages with the HVEM inhibiting the
tidylserine and soluble E-cadherin-KLRG engagements could also lead
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LCMV infection, indicating that immunopathological side
effects might arise when interfering with the PD-1 path-
way [19,20,26]. Accumulating evidence shows that HIV-
and SIV-specific CTLs express high levels of PD-1, which
contributes to the impaired proliferative T-cell responses
[21,27,28]. The control of viral load in HIV and SIV infec-
tions correlates with reduced PD-1 expression on virus-
specific CTLs, and PD-1 blockade results in enhanced
HIV- or SIV-specific CTL proliferative responses [21,27,28].
Recent findings have extended the observation that T cells
primed by HIV-pulsed DCs lead to expansion of T cells
expressing multiple inhibitory molecules to include T-cell
Ig mucin-containing domain-3 (TIM-3), lymphocyte activa-
tion gene-3 (LAG-3), and CTLA-4 besides PD-1 [2,4]. Fur-
ther, HIV-specific CD8+ and CD4+ T cells that coexpress
high levels of PD-1 and CD160 are more functionally im-
paired than cells with lower expression of these markers
[29]. Hence, it is important to investigate the association of
PD-1 with T-cell inhibition, especially in regards to the abil-
ity of virus-specific CTLs to kill infected cells. The mechan-
ism underlying the regulation of PD-1 in activated and
exhausted T cells is elusive. Recently, PD-1 upregulation via
HIV Nef was shown to occur via a p38MAPK-dependent
mechanism [30]. Several studies have confirmed that block-
ade of the STAT3, p38MAPK, NFATc, and PD-1 pathways
results in enhanced T-cell proliferation in vitro [4,5,31]. Fur-
thermore, the role of cytokine microenvironment, especially
IL-2, IL-7, IL-15, and IL-21, in different tissues is emerging
as one factor that can regulate PD-1/PD-L1 expression [32].
Importantly, transcriptional analyses of HIV-specific CD8+
T cells have shown that PD-1 could inhibit T-cell functions
by upregulating basic leucine zipper transcription factor
ATF-like (BATF) [33]. Hence, the impact of PD-1 is found
to span across many signaling cascades and transcriptional
factors, and is worth investigating.
b) CTLA-4
CTLA-4 (CD152) belongs to the costimulatory family of
molecules and represents the Ig superfamily signaling
via B7-1/B7-2 on APCs (Figure 2). It is homologous to
CD28, but unlike CD28 it is a negative regulator of
immune responses [34,35]. Unlike CD28, whose expres-
sion is constitutive, CTLA-4 expression is induced on T
cells 24–48 hours after activation and CTLA-4 has
greater affinity for both B7-1 and B7-2 than CD28.
Following T-cell activation, the sequential action of Lck,
Fyn, and RLK phosphorylates CTLA-4 and transports it
to the cell surface. This negative regulator is constitu-
tively expressed on CD4+CD25+FoxP3+ Tregs, which
suppress autoimmunity and maintain peripheral toler-
ance, whereas other T-cell subsets express this factor
only following activation [34,36]. Early studies demon-
strated that CTLA-4 was upregulated on total CD4+ Tcells of individuals with progressive HIV disease and
that there was a negative correlation between CTLA-4
expression and CD4+ T-cell count [37]. Furthermore,
studies in HIV-infected individuals at different stages of
infection revealed that CTLA-4 also is selectively
upregulated on HIV-specific CD4+ T cells in all categor-
ies of HIV-infected subjects besides long-term non-
progressors (LTNPs) [38,39]. In contrast to PD-1,
CTLA-4 is highly expressed on HIV-specific CD4+ T
cells [25,40], but absent on HIV-specific CD8+ CTLs
[38,39]. The HIV-specific CD4+ T cells with high
CTLA-4 expression have impaired cytokine production
and produce only IFN-γ, whereas cells with lower levels
of CTLA-4 have the ability to secrete both IL-2 and
IFN-γ [39]. In vitro blockade of CTLA-4 enhances HIV-
specific CD4+ T cell functions, i.e. proliferation and IL-2
production [38], and decreases the susceptibility of
these cells to become HIV infected [39].
c) TIM-3
TIM-3 belongs to the TIM family of molecules and
TIM-1 through TIM-8 exist in mice, whereas humans
express only TIM-1, TIM-3, and TIM-4 [41,42]. The
TIM family members all have certain structural morph-
ologies in common, i.e. an N-terminal immunoglobulin
V domain, a mucin domain, and a transmembrane do-
main followed by a cytoplasmic tail [41-43]. TIM-3
binds to Gal-9, an S-type lectin, and induces T-cell tol-
erance or to phosphatidylserine and induces cell death
[44,45] (Figure 2). Blocking the interaction between
TIM-3 and Gal-9 resulted in exacerbated autoimmunity
and abrogation of tolerance in experimental models
[46]. Recent studies have established that TIM-3 also
promotes CD8+ T-cell tolerance and myeloid-derived
suppressor cell (MDSC) expansion in mice [47].
TIM-3 is expressed on Th1 cells and suppresses aggres-
sive Th1 responses. TIM-3 expression is elevated on CD4+
and CD8+ T cells of HIV infected individuals [48-50]. We
have shown that TIM-3 is expressed on T cells activated
by HIV-pulsed DCs [2,4]. TIM-3 expressing T cells have
poor proliferative abilities and dysfunctional cytokine
responses, and in vitro blockade of TIM-3 results in
improved proliferative ability for the HIV-specific T cells
[50]. CD8+ T cell responses are crucial in controlling HIV-
1 infection, and their role is emphasized by the impact the
type of HLA class I alleles can have on progression to
AIDS [51,52]. Most HIV-specific CD8+ T cells upregulate
TIM-3 when interacting with their antigen epitope on
MHC I molecule complexes. Quite the opposite occurs
when HLA-B*27- and HLA-B*57-restricted HIV-specific
CD8+ T cells encounter their epitopes, which leads to less
upregulation of TIM-3 expression but higher production
of granzyme B [53]. This clearly indicates that HIV-
specific CD8+ CTLs restricted by specific haplotypes can
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and kill virus infected cells. TIM-3 and PD-1 are
coexpressed on both CD4+ and CD8+ T cells derived from
individuals with chronic HIV [54] or HCV [48,55,56]
infections and are associated with more severe CD8+
T-cell exhaustion [57]. Simultaneous blockade of PD-1
and TIM-3 pathways in vivo results in greater reversal of
T-cell exhaustion and viral control compared to when
only one of these pathways is blocked [57]. It has been
shown that the STAT3/p38MAPK pathway contributes to
upregulation of TIM-3 and therefore, it remains to be seen
if blockade of TIM-3 upregulation contributes to im-
proved functional abilities of Th1 cells in HIV infection.
d) LAG-3
LAG-3 (CD223) is a MHC II ligand belonging to the Ig
superfamily expressed on activated and memory T cells,
B cells and NK cells, and is upregulated by IL-2, IL-7
and IL-12. It is structurally homologous to the CD4 re-
ceptor, and is implicated in mediating T-cell suppres-
sion [58,59]. The LAG-3 induced T-cell suppression
reportedly occurs via CD3/TCR complex-associated
LAG-3 molecules inhibiting CD3/TCR signaling and
TCR-induced Ca2+-fluxes [60] (Figure 2). LAG-3 induc-
tion requires a weaker stimulation compared to PD-1
ligation [61].
Studies in mice models have found that LAG-3 is
capable of inducing T-cell suppression and that LAG-3
expression was linked to functional exhaustion of CD8+ T
cells in persistent infections [62-64]. CD4+CD25+ nTregs
express LAG-3 upon activation, and when this factor is
deficient, i.e. in LAG-3−/− mice, the cells exhibit impaired
regulatory activity [60], which shows that LAG-3 contrib-
utes to the suppressor functions of Tregs. Furthermore,
LAG-3 and PD-1 cooperate in the T-cell suppression and
blockade of PD-1 and LAG-3 inhibitory receptor path-
ways improve T-cell responses in a synergistic manner
[61]. However, not all data regarding LAG-3 points to a
suppressive effect. For instance, a recent study failed to
show the suppressive effects of LAG-3 [65]. LAG-3 levels
are elevated in subjects with HIV infection [59] and our
recent in vitro results are consistent with the notion that
HIV exposure could increase LAG-3 expression and that
this factor could play a negative role in HIV infection [2-4].
However, the functional relevance of LAG-3 in regulating
T cell responses in HIV infection remains to be investi-
gated further to establish if the elevated levels of this factor
are part of the immune suppression seen in HIV infection.
e) CD160
CD160 is another member of the B7/CD28 family acting
as a negative costimulatory receptor. It was originally
identified as a MHC class I activating receptor on NK cells
[64]. CD160 and BTLA binds both to the ligand HVEMexpressed on APCs and activated T cells. Today, CD160
expression has been found on cytotoxic cells such as
CD56dimCD16– NK cells, NKT cells, γδT cells, CD8+
CD28– T cells, intraepithelial T cells, and a small subset of
peripheral CD4+ and CD8+ T cells [66], and this receptor
negatively regulates cell cycle [67]. Normally, CD160 is
expressed on 5% of the CD4+ T cells, but a population of
CD4+CD160+ cells can be fond in cutaneous inflammatory
lesions [66,68]. CD160 expression is induced in a similar
manner as CTLA-4 in T cells and mediates negative sig-
naling [67]. When human CD4+ T cells are activated, they
upregulate CD160 expression and when this receptor is
cross-linked with HVEM this strongly inhibits CD4+
T-cell proliferation and cytokine production [69,70]
(Figure 2). These findings clearly confirm CD160 as a
negative regulator of CD4+ T-cell activation. The ex vivo
expression level of CD160 is augmented in the lymphatic
tissues derived from HIV-1-infected individuals during the
acute stage of the disease [71]. In addition, CD160 expres-
sion is increased in acute and chronic HIV infections both
on CD8+ T cells in general and on HIV-specific CD8+ T
cells [28,71], which is in line with our recent observations
in vitro [2,4]. Blockade of CD160 ligation with HVEM
improves HIV-specific CD8+ T-cell proliferation and
cytokine levels [29]. Recently, it has been reported that
CD160+PD-1+CD8+ T cells define a subset at an advanced
stage of immune exhaustion [29] and this underlines the
importance of co-expression of inhibitory molecules in
HIV-associated T-cell exhaustion.
f) BTLA
BTLA (CD272) is a negative costimulatory molecule be-
longing to the B7/CD28 family. BTLA is constitutively
expressed at low levels on naïve B and T cells, macro-
phages, DCs, NKT cells, and NK cells [66]. It binds to its
cognate ligand HVEM, a member of the TNFR super-
family expressed on APCs and Tregs [66]. BTLA expres-
sion is upregulated following T-cell activation. Similarly to
CD160, BTLA has impairing effects on the cell cycle
(Figure 2) [69] and inhibits TCR-mediated signaling via
ITIM and ITSM motifs [72]. Engagement of BTLA on T
cells with its ligand HVEM inhibits effector CD4+ T-cell
functions [66,69,70]. Although BTLA has been proposed
to be a negative regulator of T-cell activation, its potential
inhibitory function is still inconclusive in HIV-1 infection.
Our studies showed that BTLA upregulation was indis-
tinctive on HIV-infected T cells in vitro [2,4] while others
have reported that HIV-1 infection could downregulate
BTLA on CD4+ and CD8+ T cells [73,74]. A recent finding
demonstrated that HIV-1 could induce BTLA down-
regulation on CD4+ T cells in vitro in an IFN-α dependent
manner and this contributed to T-cell hyperactivation
[73]. In agreement with this, dysregulation of B cells in
HIV-1 infection has been associated with decreased BTLA
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to aviremic individuals and healthy controls [1]. However,
the functional significance of BTLA in HIV infection
needs to be further evaluated.
g) 2B4
2B4 (CD244) belongs to the signaling lymphocyte
activation molecule (SLAM) family whose members are
implicated in the regulation of costimulation, cytokines,
and cytotoxic activities [75]. This transmembrane pro-
tein is expressed by all NK cells, monocytes, basophils,
eosinophils, γδ T cells, and memory CD8+ T cells [75].
CD48 is the cognate ligand of 2B4 and is expressed on
NK cells [76]. 2B4 is an inhibitory receptor [77] regulat-
ing CD8+ T-cell functions and its expression could be a
marker of CD8+ T-cell impairment [76]. Cross-linking
of 2B4 with anti-2B4 mAb leads to NK-cell activation
[76]. However, elevated 2B4 expression and relative pau-
city of signaling of 2B4’s intracellular adaptor molecule
SAP promote an inhibitory function of 2B4 (Figure 2)
[76,78]. Studies have shown that 2B4 expression on NK
cells is increased in HIV-1 infected patients [79]. Fur-
ther, the proportion of 2B4+CD8+ T cells is associated
with immune activation of memory T cells, which
increases with disease progression [80]. It is also clear
that the ability to produce IFN-γ and cytotoxic activity
of HIV-specific 2B4+CD8+ T cells is relatively lower
compared to influenza-specific 2B4+CD8+ T cells in
HIV infected individuals [81], and in vitro blockade of
2B4 increases the proliferative capacity of HIV-specific
CD8+ T cells [82]. Moreover, downregulation of SAP in
2B4+CD8+ T cells upon HIV stimulation suggests an
inhibitory role of 2B4+CD8+ T cells against constrained
HIV epitopes, underlining the inability to control HIV
during disease progression.
h) LILRB
Members of the leucocyte immunoglobulin-like recep-
tor B (LILRB) family are expressed on B cells, mast cells,
macrophages, monocytes, osteoclasts, NK cells and DCs
[83,84] and are the human counterpart of the murine
inhibitory molecule, PIR-B. Research has shown that
LILRB1 can also be a T-cell factor that binds to HLA-A,
HLA-B, HLA-F, HLA-G, and HCMV UL18 ligands
[83,84]. DCs interaction with suppressor molecules on
regulatory T cells rendered them tolerogenic by indu-
cing upregulation of LILRB2 and LILRB4 [84]. High
levels of LILRB1 and LILRB2 are observed during
chronic HIV infection [85-87] and it has been shown
that IL-10 upregulates LILRB2 in the monocytes of
HIV-infected individuals, resulting in CD4+ T cell deple-
tion [88]. However, LILRB1 and LILRB3 expression on
circulating myeloid DCs of HIV elite controllers con-
tributes to greater antigen-presenting potentials andtheir blockade abrogates the antigen-presenting proper-
ties of DCs [89]. This indicates that the regulatory func-
tions of various members of the LILRB family are
multifaceted.
i) TRAIL
TRAIL is a member of the TNF superfamily, and func-
tions as a proapoptotic ligand [90]. The two biologically
active forms of TRAIL, membrane-bound (mTRAIL)
and soluble TRAIL (sTRAIL), are regulated by type I
IFNs [91,92]. sTRAIL is secreted by leukocytes, includ-
ing T cells, NK cells, DCs, monocytes, and macrophages
[90,91,93]. TRAIL can interact with DR4 and DR5
receptors, capable of inducing apoptosis [93,94] and
three other receptors that facilitate suppression without
initiating apoptosis [93] (Figure 2). The elevated
mTRAIL levels on T cells exposed to HIV-pulsed DCs
[2,4] is intriguing because it can negatively regulate pro-
liferation via mechanisms distinct from apoptosis [90].
Studies have shown that TRAIL is elevated in HIV-
infected compared to uninfected subjects, and that
when ART lowers the viral load dramatically, the TRAIL
expression decreases [90]. Hence, TRAIL could be one
potential inhibitory factor contributing to T-cell sup-
pression in HIV infection.
j) KLRG1
KLRG1 is a member of the C-type lectin family of
inhibitory receptors, which plays a unique but poorly
characterized role in mediating T-cell exhaustion
[95,96]. Soluble E-cadherin is the ligand for KLRG1.
KLRG1 is expressed on a subset of CD4+ and CD8+ T
cells, as well as on NK cells, and inhibits CD8+ T cell
cytotoxicity and cytokine production [95,96] (Figure 2).
KLRG1 is upregulated on virus-specific CD8+ T cells in
response to repetitive antigenic stimulation in PVIs
such as CMV and EBV [95,96]. The presence of the
KLRG1 ligand, soluble E-cadherin, impairs the KLRG1hi
HIV-1–specific CD8+ T cells’ ability to respond by cyto-
kine secretion upon antigenic stimulation and to inhibit
viral replication [77]. Furthermore, KLRG1 is coexpresssed
with other inhibitory receptors, i.e. PD-1, CD160, and
2B4, on exhausted HCV-specific CD8+ T cells [77]. Of
note, a recent study showed that knockout of KLRG1 in
mice did not have an apparent effect on the phenotype,
suggesting that KLRG1 might not contribute significantly
to T cell exhaustion during HIV infection [97].
Transcriptional factors and pathways
Recent lines of evidence have highlighted the importance
of inhibitory molecules and related pathways of T-cell
exhaustion. However, the underlying transcriptional
mechanisms remain for the most part elusive. In addition
to the multiple inhibitory receptors that are involved in
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terns are observed when comparing the molecular signa-
tures of exhausted T cells to functional T cells. These
changes include altered expression of transcription factors,
changes in signal transduction, and down-regulation of
key metabolic genes [2].
a) BLIMP-1
BLIMP-1 (designated PRDI-BF1 in humans), a zinc finger-
containing evolutionarily conserved transcriptional repres-
sor encoded by PRDM1, is an important factor implicated
in the generation of terminally differentiated plasma cells
[98]. BLIMP-1 has also been reported to be a master regu-
lator of terminal differentiation of CD8+ T-cells [99].
Recently, it has been shown that its elevated expression
directly correlates with the upregulation of an array of cell
surface inhibitory molecules in chronic viral infection [63]
(Figure 1). BLIMP-1 attenuates T-cell proliferation and
CD4+ Treg functions, and its expression is reportedly en-
hanced in antigen-experienced T cells [100-102]. BLIMP-1
promotes the overexpression of inhibitory receptors and
also suppresses key molecules involved in normal memory
CD8+ T-cell differentiation, such as IL-7 receptor and
CD62L [63]. Moreover, coexpression of FoxP3 and
BLIMP-1 could be vital for suppressor functions as FoxP3
reportedly leads to activation of BLIMP-1 in antigen-
exposed T-cells [102]. Intriguingly, high BLIMP-1 expres-
sion correlates with increased PD-1, CTLA-4, and CD160
expression in chronic HIV infection [63]. During acute
infection, smaller amounts of BLIMP-1 are associated with
terminal differentiation of effector FoxP3+CD8+ T cells
[102], whereas high BLIMP-1 expression during chronic
infection promotes upregulation of inhibitory receptors
including PD-1, LAG-3, CD160 and 2B4, resulting in
exhausted CD8+ T cells [63]. While lack of BLIMP-1 gives
defective cytolytic function in virus-specific CD8+ T cells
and low expression of KLRG1 [77], the potential role of
BLIMP-1 in the upregulation of multiple inhibitory mole-
cules is clear in chronic viral infections, especially in
LCMV and HIV-1 infection [2,4,63,103]. We have demon-
strated that BLIMP-1 is induced in CD4+ T cells stimu-
lated by HIV-exposed DCs [2,4] and recent lines of
evidence points to the existence of a novel miR-9/BLIMP-
1/IL-2 axis that is compromised in progressive HIV dis-
ease but not in LTNPs [104,105]. BLIMP-1 is upregulated
in CD4+ T cells via TCR stimulation and IL-2 and this is
regulated by miR-9 levels. The upregulation of miR-9
induces BLIMP-1 repression, leading to restoration of IL-2
secretion by CD4+ T cells, which occurs by reduced bind-
ing potential of BLIMP-1 to the il-2 promoter [104,105].
b) FoxP3
FoxP3 regulates CD4+T-cell activation and FoxP3 ex-
pression is elevated in T cells upon stimulation leadingto suppressive functions (Figure 1) [106] and HIV and
SIV infections can give rise to FoxP3 expression in T
cells [106-111]. Recent findings associated increased Fox
P3 expression with the onset of T cell dysfunction in
HIV/AIDS [112]. Interestingly, high CTLA-4 expression
on Tregs depends on FoxP3 along with NFAT [111,113].
The elevated expression of FoxP3 and BLIMP-1 in T
cells primed with HIV-pulsed DCs suggests a potential
direct role of FoxP3 in controlling BLIMP-1 expres-
sion in antigen-exposed T cells [2,4]. This is consistent
with prior observations from a genome-wide inves-
tigation, which showed that BLIMP-1 is directly activated
by FoxP3, adding a key dimension to the notion that
BLIMP-1 is necessary for accurate function of suppressor
T cells [101].c) T-bet
T-bet, encoded by Tbx21 gene, is the key regulator of the
Th1 phenotype differentiation system. It induces the syn-
thesis of IFN-γ and regulates the expression of che-
mokines and chemokine to orchestrate Th1 cell
differentiation. Expression of T-bet together with
granzyme A and B, granulysin, and perforin has been
assessed in HIV-specific CD8+ T cells derived from elite
controllers, progressors, and ART treated individuals
[114]. Interestingly, the HIV-specific CD8+ T cells from
elite controllers had greater capacity for granzyme B and
perforin expression relative to the other groups [114]
and level of T-bet expression in HIV-specific CD8+ T
cells correlated with granzyme B and perforin levels
[114]. Hence, it has been suggested that T-bet can regu-
late the expression of perforin and granzyme B by bind-
ing to the promoter regions of these genes [115-117]. In
chronic LCMV, T-bet directly represses the gene pro-
motor for PD-1 in a site-specific manner, which leads to
lower expression of PD-1 and other inhibitory receptors
[117,118]. It was also demonstrated that genetic abla-
tion of T-bet leads to exacerbation of CD8+ T-cell
exhaustion and increase of viral load [118]. BLIMP-1
and T-bet seem to have similar roles in promoting the ef-
fector function and terminal differentiation of CD8+ T
cells during acute infection [102,117]. High T-bet expres-
sion promotes terminally differentiated CD127loKLRG-1hi
effector CD8+ T cells and sustains functional virus-specific
CD8+ T-cell responses [117]. Exhausted CD8+ T cells have
downmodulated T-bet levels due to persistent antigenic
stimulation results in exhausted CD8+ T cells [117].
Whereas the exact mechanism of repression of T-bet ex-
pression is unknown, deficiency of T-bet leads to attenu-
ated BLIMP-1 expression in NK cells [119], and the same
effect may be expected in the CD8+ cell, as BLIMP-1 and
T-bet-deficient CD8+ T cells show similar differentiation
phenotypes [102,120,121].
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BATF has been identified as a negative regulator of AP-1
by forming dimers with c-Jun [122], which inhibit canon-
ical AP-1-mediated transcription, and this contributes to
T cell exhaustion [123]. BATF regulates effector CD8+
T-cell differentiation via Sirt1 expression [124,125]. PD-1
ligation can inhibit T cell functions by enhancing BATF
expression and this has been documented in HIV-specific
CD8+ T cells derived from infected individuals [33]. It has
also been shown that BATF overexpression in activated
primary human T cells impairs T-cell proliferation and
IL-2 production, whereas silencing BATF expression in
HIV-specific T cells increases their proliferation, as well as
IFN-γ and IL-2 production [33,124], confirming that
BATF plays a role in T cell dysfunction during HIV infec-
tion. In addition, BATF is also required for the differenti-
ation of IL17-producing Th17 cells, which coordinate
inflammatory responses in host defense [125].e) p38MAPK/STAT3
The STAT3 pathway can be activated either by IL-10 and
IL-6 cytokines or by growth factors such as VEGF, TGF-β,
G-CSF, PDGF, EGF and MAPkinases [126,127]. Recently,
we have reported that p38MAPK/STAT3 pathways were
involved in HIV-1 mediated upregulation of inhibitory
receptors CTLA-4, TRAIL, TIM-3, LAG-3, CD160 and
transcription factors BLIMP-1, DTX1, and FoxP3, as their
blockade abolished expression of inhibitory molecules and
restored T-cell proliferation in vitro [4]. Specifically, it has
been found that HIV Nef mediates PD-1 upregulation via
a p38MAPK-dependent mechanism [30].g) NFATc1 and DTX1
An impaired NFAT nuclear translocation is observed in
exhausted CD8+ T cells during chronic HIV and LCMV
infections [128,129]. The nuclear translocation of
NFATc1 (NFAT2) was more efficient in HIV-specific
CD8+ T cells derived from LTNPs relative to individuals
with disease progression [130]. Inhibition of calcineurin
or NFAT leads to sharp reduction in PD-1 expression
suggesting a regulatory role for calcineurin/NFAT
signaling pathway [129,130]. However, it remains to be
investigated how altered nuclear translocation of NFATc1
and PD-1 expression are associated with exhausted T
cells. DTX1 is a transcription target of NFAT, and
upregulation of DTX1 inhibits T-cell activation by both
E3-dependent and E3-independent mechanisms [131].
Recently, we reported that HIV-1 induced increased
expression of DTX1 mRNA in the T cells primed by
HIV-1 exposed DCs, which correlated with increased
NFAT mRNA [4]. We also found that inhibition of
NFAT decreased DTX1 and PD-1 mRNA and protein
expression.h) Miscellaneous pathways
FOxO3a FOxO3a is a transcription factor constitutively
expressed in hematopoietic cells that can promote the
transcription of certain proapoptotic target genes e.g. Bim,
FasL, and TRAIL [132]. HIV TAT-induced FOXO3a in as-
sociation with these factors reportedly play a major role in
mediating the apoptosis of HIV-1-infected human CD4+ T
cells [133]. A study showed that FOxO3a/TRAIL signaling
has a direct role in the persistence of memory B cells dur-
ing HIV infection [134]. Transcriptional activity of
FOxO3a and expression of TRAIL have been found to be
higher in aviremic treated individuals compared to elite
controllers and uninfected individuals and have been at-
tributed to low survival rates of memory B cells [134].
Socs3 Socs3 has recently been shown to facilitate T-cell
exhaustion in chronic infections [135]. LCMV-specific T
cells in chronic infection express higher levels of Socs3,
whereas Socs3 deficiency leads to enhanced T cell func-
tions. Interestingly, IL-7 treatment results in decreased
levels of Socs3 and reinvigorates the immune response to
chronic virus infection [135,136]. Hence, downregulation
of Socs3 using IL-7 is likely to contribute to improve
T-cell functions. The role of Socs3 in HIV-1 infection re-
mains to be investigated.
Hippo pathway The Hippo pathway is a highly conserved
developmental system, which directly controls terminal
differentiation of multiple cell types in invertebrates and
vertebrates [137]. Recently, it was shown that activation of
the Hippo pathway by CTLA-4 regulates the expression of
BLIMP-1 in CD8+ T cells [121]. The CTLA-4/Hippo path-
way/BLIMP-1 system may link terminal differentiation of
CD8+ T cells [121]. However, the precise role of the associ-
ation of CTLA-4/Hippo/BLIMP-1 network in HIV infec-
tion remains to be elucidated.
Immunoregulatory cytokines and enzymes
a) IDO
IDO is an intracellular enzyme that catalyses the catabol-
ism of tryptophan. IFN-γ is the primary inducer of IDO
while other factors such as TNF-α, TNF-β and lipopoly-
saccharide can induce IDO to a limited extent [138,139].
In 2002, it became evident that CTLA-4 ligation to B7
resulted in the induction of an IDO+ immunosuppressive
DC phenotype (Figure 1) [40]. Subsequently, CTLA-4/B7-
mediated IDO induction was observed in myeloid DCs,
pDCs, and MDDCs [140,141]. Increased IDO activity
leads to apoptosis of effector T cells and induction of
Tregs thereby dampening an active immune response
[142]. These Tregs participate in a positive feedback loop
via CTLA-4 engagement of B7 molecules, which stimulate
increased IFN-γ production from APCs and subsequent
enhancement of IDO activity [142]. The reduction of
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first reported in 1988 [143] and thereafter it has been
shown that HIV infection could result in increased IDO ac-
tivity [144]. It is becoming clear that TGF-β1 signaling
through a PI3K-dependent or a SMAD-independent path-
way can induce Fyn-dependent phosphorylation of IDO
ITIMs [145], which leads to activation of noncanonical NF-
kB to activate IDO signaling [145]. Therefore, approaches
blocking the IDO pathway may be a potential strategy to
improve T-cell functions in HIV-infected patients.
b) IL-10
IL-10 was first recognized for its ability to inhibit activa-
tion of T cells, B cells, monocytes, and macrophages, and
also to terminate inflammatory responses [146,147]. IL-10
is produced by CD4+ T cells, including Tregs, CD8+ T
cells, DCs, macrophages, and B cells [146,147]. Increase in
IL-10 levels has been reported in PVIs, including HIV and
HCV [148]. Interestingly, it has been shown that IL-10
and PD-L1 pathways work in synergy to suppress T-cell
activation during persistent LCMV infection, and that
blockade of both IL-10 and PD-L1 more effectively
restores antiviral T-cell responses than blockade of either
one alone [149]. The PD-1–induced IL-10 production by
monocytes could impair CD4+ T cell activation during
HIV infection [150]. Furthermore, the levels of serum IL-
10 and IL-10 mRNA in PBMCs are reported to increase
with HIV disease progression [151] and IL-10 reversibly
inhibits virus-specific T cells [152]. Blockade of IL-10
restored Env- specific T-cell proliferative responses to a
high degree [153], although, this ability was eventually lost
during advanced HIV disease [152].
c) TGF-β
TGF-β is an immunoregulatory cytokine that is implicated
in controlling immune responses and maintaining immune
homeostasis by affecting proliferation, differentiation,
and survival of multiple immune cell lineages [154].
Upregulation of TGF-β and IL-10 is associated with disease
progression in HIV-1-infected individuals [155]. TGF-β
upregulates CTLA-4 expression and suppresses IL-2 pro-
duction and T cell proliferation [156]. Moreover, it has been
reported that TGF-β and IL-10 production by HIV-specific
CD8+ T cells regulates CTLA-4 signaling on CD4+ T cells
[155]. Noteworthy is that blockade of TGF-β did not im-
prove control of chronic LCMV infection [157,158], which
suggests that blocking this factor alone might not have any
effect on the control of HIV-1 infection.
Conclusion
Our improved understanding of the T-cell costimulation
and coinhibition pathways attained over the past decade
has given plenty of evidence on the key roles played by
these molecules in immune homeostasis. However,numerous infectious agents and tumors escape from
host immune surveillance by efficiently upregulating
coinhibitory signals. It is now clear that coexpression of
multiple distinct inhibitory receptors is associated with
greater T cell exhaustion and rapid HIV disease progres-
sion. It has also been established by researchers that
T-cell inhibition results from progressive sequential
accumulation of a broad array of inhibitory molecules in
HIV infection. Hence, measures to understand their
contribution to T-cell suppression and target the mo-
lecular and biochemical signaling networks that con-
verge to inhibit T-cell activation need to be further
investigated. Our recent findings have shown that in-
hibitory molecules are under the control of diverse
pathways, i.e. PD-1 is upregulated by both p38MAPK/
STAT3 and NFAT pathways, whereas CTLA-4, TRAIL,
LAG-3, CD160 and TIM-3 are regulated by p38MAPK/
STAT3. Of interest to further elucidate is for instance
how HIV-1 exploits DCs, inducing them to secrete retin-
oic acid, which is believed to trigger the differentiation of
tolerogenic T cells. Further, it is clear that inhibitory recep-
tors are potential targets of therapeutics in HIV infection
and therefore it is important to decode the molecular sig-
natures of T-cell suppression as this might open up for
new drugs targeting inhibitory molecules, transcriptional
repressors and pathways in HIV infected individuals.
Although there is no experimental evidence, one ap-
proach we suggest is to block inhibitory molecules, espe-
cially PD-1/PD-L1, to amplify antiviral T-cell functions to
a level sufficient enough to purge latent viral reservoirs.
Certain key questions still remain to be answered; will the
therapeutic use of targeting inhibitory molecules in HIV
be toxic to HIV-infected individuals? What will be the
magnitude of damage caused to the house-keeping func-
tions of the coinhibitory molecules targeted? Will this
targeting bring any additional benefit to ART-treated sub-
jects? Exploring these areas may be necessary to ensure
successful response of chronic HIV infected patients to
anti-inhibitory molecular therapeutics. Therefore, the
prime objective would be to facilitate complete functional
restoration of T-cell functions, which may rely on combin-
ation therapies targeting diverse sets of host cellular fac-
tors at different stages of HIV infection. Given the
emergence of a wider network of inhibitory molecules in
HIV infection, additional studies may be required to inves-
tigate the molecular targets associated with restoration of
T-cell functions to increase longevity and quality of life of
HIV-infected individuals.
Definitions
Exhausted T cells Memory T cells that assume a state of
unresponsiveness following activation by certain viral anti-
gens that are noticeable during subsequent antigenic
stimulation [159].
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1. Natural Tregs (nTregs) CD4 + CD25 + CD127low
phenotype cells that develop in the thymus. nTregs are
CTLA-4 + GITR + Foxp3+. They facilitate auto reactive
T-cell suppression by contact, cytolytic mechanisms,
or by TGF-β. nTregs expand in vivo following TCR/
CD28 stimulation and by expressing receptors for IL-2.
2. Induced Tregs (iTreg) Non-regulatory CD4+ T cells,
which acquire CD25 (IL-2Rα) expression outside of the
thymus. a) Tr1: CD4 + CD25- phenotype that develops in
the periphery. Tr1 cells are marked by CD45RBlowFoxp3-
and mediate suppression via IL-10. Tr1 cells expand
following CD3 signaling leading to secretion of IL-10 and
retinoic acid. b) Tr3: CD4 + CD25+, develop in the
periphery under the influence of TGF-β from CD4+
CD25-Treg precursors. Tr3 cells are marked by
CD25low-variableCD45RBlowFoxp3+ and mediate sup-
pression via TGF-β. Expand following CD3 signaling
leading to secretion of TGF-β.
Suppressor T cells T cells that arise following priming by
HIV-exposed DCs. Suppressor T cells reportedly express
numerous molecules that could facilitate T-cell inhibition
in a contact-dependent manner [2-4].
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